The Best of Wound Healing 2017

2017 went by in a hurry – as every year has a way of doing. In case you missed any of last years blogpost, we’ve gathered some of our top posts and made a collection for you! You’ll find them below. 2017 was an exciting and important year for the Woulgan team. We kicked off … Continue reading ›

Reactivating stalled wounds with soluble beta-glucan

Inflammation is a natural response to the formation of a wound, denoting that the body’s microbiological processes are actively trying to repair the ulcer site. The uptick in microbiological activity appears as inflammation, redness and warmth around the wound. However, excess, uncontrolled long-term inflammation is a sign that the body’s immune system is not functioning … Continue reading ›


Explore more blog posts

Woulgan User Guidance Video

The Woulgan team is proud to present the new Woulgan user guidance video! “A picture speaks more than a thousand words” is a famous saying. With the time restrictions experienced by nurses, we hope that our brand new video will help you to get a quick grasp of how Woulgan reactivates stalled healing, how to … Continue reading ›

Management approaches to restart healing in stalled wounds

At any point in the healing trajectory, a wound can become stalled. That is, the wound initially began to heal, but patient- or wound-related factors have prevented the wound from continuing to heal in an orderly and timely manner. The wound is stuck — ‘stalled’ — in the inflammatory phase, as indicated by a lack … Continue reading ›

Wound care: A costly epidemic

The costs of obesity to the health care system are plastered across the headlines — and yet, few recognise that the financial impact of caring for wounds is similar to that of obesity.[1] In fact, an estimated 2–4% of healthcare expenditure across Europe is eaten up by wound care.[2] A lot of this wound care … Continue reading ›

Soluble Beta-Glucan and Woulgan: A Brief Timeline

Biotec BetaGlucans’ work on beta-glucan activity has roots in discoveries made at the University of Tromsø, Norway, and Biotec Pharmacon’s early work developing a portfolio of beta-1,3/1,6-glucan products that have been sold worldwide in the animal health and consumer markets. Despite its origins in the Arctic Circle, the company has since closely collaborated with leading … Continue reading ›